Prescription drug · NDA
Mektovi (binimetinib) NDC 70255-010
Binimetinib 15 mg/1 · Tablet, Film coated · Oral · Array BioPharma Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70255-010-02 | 70255001002 | 1 BOTTLE in 1 CARTON (70255-010-02) / 180 TABLET, FILM COATED in 1 BOTTLEMarketed from Jun 27, 2018 | |
| 70255-010-03 | 70255001003 | 90 TABLET, FILM COATED in 1 BOTTLE (70255-010-03)Marketed from Jun 27, 2018 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Mektovi
- Generic name (nonproprietary)
- binimetinib
- Active ingredients
- Binimetinib — 15 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Array BioPharma Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 210498
- Marketing start
- Listing expires
- Identifiers
- Product ID 70255-010_36941d95-638d-4a3c-8888-209eea0e0722SPL ID 36941d95-638d-4a3c-8888-209eea0e0722SPL set ID 6c3408ac-d401-4925-8a03-26591afbc240RxCUI 2049127, 2049133UNII 181R97MR71
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470255001002followed by a unit qualifier and the quantityPackage 70255-0010-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-a…
Excerpt only. Read the full label for complete information.